The potential for antitumor vaccination in acute myelogenous leukemia

Journal of Molecular Medicine

Volumn 76, Issue 2, 1998, Pages 80-93

  Arceci, Robert J ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Cancer vaccines; Costimulation; Cytokines; Immunotherapy

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL MODEL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NONHUMAN; REVIEW; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; VACCINATION;

EID: 0031882130     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050195     Document Type: Review

References (180)

1. Arceci RJ (1993) Clinical significance of P-glycoprotein in multidrug resistance melignancies. Blood 81:2215-2222
2. Borst P (1991) Genetic mechanisms of drug resistance. A review. Acta Oncol 30:87-105
3. Nooter K, Herweijer H (1991) Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63:663-669
4. Weisnstein HJ, Griffin JD (1995) Acute myelongenous leukemia. In: Handin RI, Lux SE, Stossel TP (eds) Blood: principle and practice of hematology. Lippincott, Philadelphia, pp 543-574
5. Gupta RS, Goldstein S (1982) Human fibroblast strains showing increased sensitivity or resistance to ethidium bromide. Mut Res 105:183-188
6. Tedeschi B, Porfirio B, Vernole P, Caprossi D, Dallapiccola B, Nicoletti B (1987) Common fragile sites: their prevalence in subjects with constitutional and acquired chromosomal instability. Am J Med Genet 27:471-482
7. Auerbach AD (1995) Fanconi anemia. Dermatol Clin 13:41-49
8. Ellis NA, Groden J, Ye TZ, Straughen J, Lennon DJ, Ciocci S, Proytcheva M, German J (1995) The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 83:655-666
9. Old LJ, Boyse EA (1964) Immunology of experimental tumors. Annu Rev Med 15:167-186
10. Currie GA (1972) Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. Br J Cancer 25:142-153
11. Southam CM (1960) Relationships of immunology to cancer: a review. Cancer Res 20:271-291
12. Gross L (1943) Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 3:326-333
13. Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13:835-837
14. Gorer PA, Amos DB (1956) Passive immunity in mice against C57BL leukosis EL4 by means of isoimmune serum. Cancer Res 16:338-343
15. Coley-Nauts H, Swift WE, Coley BL (1946) The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res 6:205-216
16. Mathe G, Amiel JL, Sehwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, De Vassal F 81969) Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1:697-699
17. Heyn RM, Joo P, Karon M, Nesbit M, Shore N, Breslow N, Weiner J, Reed A, Hamond D (1975) BCG in the treatment of acute lymphocytic leukemia. Blood 46:431-142
18. Andrein JM, and the European Organization for Research on Treatment of Cancer Hemopathies Working Party (1978) Immunotherapy versus chemotherapy as maintenence treatment of acute lymphoblastic leukemia. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer: present status of trials in man. Raven. New York, pp 471-481
19. Poplack DG, Graw RG, Pomeroy TC et al (1978) Immunotherapy of acute lymphatic leukemia with bacillus Calmette Guerin (BCG) and allogeneic leukemia cells. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer: present status of trials in man. Raven, New York, pp 497-501
20. Gutterman JU, Hersh EM, Rodriguez V, McCredie KB, Mavligit G, Reed R, Burgess MA, Smith T, Gehan E, Bodey GP Sr, Freireich EJ (1974) Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G. Lancet II:1405-1409
21. Powles R (1974) Immunotherapy for acute myelogenous leukemia using irradiated and unirradiated leukemia cells. Cancer 34 [Suppl]: 1558-1562
22. Powles RL, Lister TA, Crowther D, McElwain T, Alexander P, Fairley GH (1975) Immunotherapy for acute myelogenous leukemia. Bibl Haematol:737-749
23. Powles R (1973) Immunotherapy of acute myelogenous leukemia in man. Natl Cancer Inst Monogr 39: 243-247
24. Powles RL, Balchin LA, Fairley GH, Alexander P (1971) Recognition of leukemia cells as foreign before and after autoimmunization. Br Med J 1:486-489
25. Holland JF, Bekesi JG (1976) Immunotherapy of human leukemia with neuraminidase-modified cells. Med Clin N Am 60:539-549
26. Ohno R, Nakamura H, Kodera Y, Ezaki K, Yokomaku S, Oguma S, Kubota Y, Shibata H, Ogawa N, Masaoka T, Kazuma Y (1986) Randomized controlled study of chemoimmunotherapy of acute myelogenous leukemia (AML) in adults with Nocardia rubra cell-wall skeleton and irradiated allogeneic AML cells. Cancer 57:1483-1488
27. Hayat M, Jehn U, Willemze R, Haanen C, Zittoun R, Monconduit M, Lowenberg B, Stryckmans P, Peetermans M, De Cataldo F, Kerkhofs H, Abels J, Klein H, Andreien J, Goudsmit R, Cauchie C, Suciu S, Solbu G (1986) A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC. Cancer 58:617-623
28. Granatek CH, Ezaki K, Hersh EM, keating MJ, Rasmussen S (1981) Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy. Cancer 47:272-279
29. McCredie KB, Bodey GP, Freireich EJ, Hester JP, Rodriguez V, Keating MJ (1981) Chemoimmunotherapy of adult acute leukemia. Cancer 47:1256-1261
30. Summerfield GP, Gibbs TJ, Bellingham AJ (1979) Immunotherapy using BCG during remission induction and as the sole form of maintenance in acute myeloid leukaemia. Br J Cancer 40:736-742
31. Petersen, ELC, Hokland P, Ellegaard J (1983) Adjuvant immune stimulation with Corynebacterium parvum during maintenance chemotherapy of acute myeloid leukemia. Cancer Immunol Immunother 16:88-92
32. Urbanitz D, Buchner T, Pielken H, Koch P, Ludwig WD, Maschmeier G, Heinecke A, van de Loo J (1987) Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial. Hamatol Bluttransfusion 30:64-68
33. Alsabti EA, Taleb AM, Raji HM, Kalil OZ, Saleh KA (1979) Clinical trials in vaccination with leukemia associated antigens in acute myelogenous leukemia. Jpn J Exp Med 49:157-168
34. Foon KA, Gale RP (1982) Controversies in the therapy of acute myelogenous leukemia. Am J Med 72:963-979
35. Foon KA, Smalley RV, Riggs CW, Gale RP (1983) The role of immunotherapy in acute myelogenous leukemia. Arch Intern Med 143:1726-1731
36. Laursen ML (1988) Immunotherapy in acute myelogenous leukemia (AML) - a tool for maintaining remission? Med Hypotheses 26:221-225
37. Foon KA, Smalley R, Riggs CW, Gale RP (1983) The role of immunotherapy in acute myelogenous leukemia. Arch Intern Med 143:1726-1731
38. Urbanitz D, Pielken HJ, Koch P, Buchner T, Hiddemann W, heinecke A, Wendt F, Maschmeier G, van de Loo J (1985) Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy. Onkologie 8:157-159
39. Zuhrie SR, Harris R, Freeman CB, MacIver JE, Geary CG, Delamore IW, Tooth JA (1980) Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia. Br J Cancer 41:372-377
40. Slavin S, Weiss L, Ackerstein A, Vourka-Karussis U, Morecki S, Or R, Nagler A, Kapelushnik J, Delukina M, Drakos P, Naparstek E (1993) Prevention and treatment of relapse by bone marrow transplantation. Bone Marrow Transplant 12: S54-S56
41. Casper J, Camitta B, truitt R, Baxter-Lowe LA, Bunin N, Lawton C, Murray K, Hunter J, Pietryga D, Garbrecht F, Taylor CK, Drobyski W, Horowitz M, Flomenberg N, Ash R (1995) Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 85:2354-2363
42. Johnson BD, Truitt RL (1995) Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 85:3302-2212
43. Korngold R, Leighton C, Manser T (1994) Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 58:278-287
44. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, O'Reilly RJ (1995) Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 15:591-594
45. Pati AR, Godder K, Lamb L, Gee A, Henslee-Downey PJ (1995) Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marow Transplant 15:979-981
46. Porter DL, Antin JH (1995) Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. Leukemia Lymphoma 17:191-197
47. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041-2050
48. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, Carroll A, Inoue S, Camitta B, Weinstein HJ (1996) Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 334:1428-1434
49. Woods WG, Kobrinsky JD, Lee JW, Sanders J, Neudorf S, Gold S, Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur DC, Lange BJ (1996) Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 87:4979-4989
50. Pardoll D (1994) Tumor antigens: a new look for the 1990s. Nature 369:357-358
51. Slingluff CL, Hunt DF, Engelhard VH (1994) Direct analysis of tumor-associated peptide antigens. Curr Opin Immunol 6:733-740
52. Ostrand-Rosenberg S (1994) Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 6:722-727
53. Coulie PG (1995) Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination? Stem Cells 13:393-403
54. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92:7976-7980
55. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W (1995) Immunity to oncogenic proteins. Immunol Rev 145:33-59
56. Van Pel A, van der Bruggen, P, Coulie PG, Brichard VG, Lethe B, van den Eynde B, Uyttenhove C, Renauld JC, Boon T (1995) Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229-250
57. Boel P, wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167-175
58. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365
59. Boon T (1993) Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 54:177-180
60. Boon T, Gajewski TF, Coulie PG (1995) From defined human antigens to effective immunization? Immunol Today 16:334-336
61. De Plaen E, Lurquin C, Van pel A, Mariame B, Szikora, J-P, Wolfel T, Sibille C, Chomez P, Boon T (1988) Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum-antigen P91A and identification of the tum-mutation. Proc Natl Acad Sci USA 85:2274-2278
62. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T (1991) The gene coding for a major tumor rejection antigen of tumor p815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173:1373-1384
63. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458-6462
64. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA (1992) Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2,1-transfected melanomas. J Immunol 148:638-643
65. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515-3519
66. Kawakami Y, Eliyahu S, jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen pg 100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-1968
67. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA (1995) Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181:799-804 (published erratum 181:1261)
68. de Bergeyck V, De Plaen E, Chomez P, Boon T, Van Pel A (1994) An intracisternal A-particle sequence codes for an antigen recognized by syngeneic cytolytic T lymphocytes on a mouse spontaneous leukemia. Eur J Immunol 24:2203-2212
69. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719
70. Slingluff CL, COX AL, Henderson RA, Hunt DF, Engelhard VH (1993) Recognition of human melanoma cells by HLA-A2,1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J Immunol 150:2955-2963
71. Engelhard VH, Appella E, Benjamin DC, Bodnar WM, Cox AL, Chen Y, Henderson RA, Huczko EL, Michel H, Sakaguchi K, Shabanowitz J, Sevilir N, Slingluff CL, Hunt DF (1993) Mass spectrometric analysis of peptides associated with the human class I MHC molecules HLA-A2,1 and HLA-B7 and identification of structural features that determine binding. Chem Immunol 5739-5762:39-62
72. Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr. Bloon T, Hunt DF, Engelhard VH (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527-534
73. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH (1992) Characterization of peptides bound to the class 1 MHC molecule HLA-A2,1 by mass spectrometry. Science 255:1261-1263
74. Woods AS, Huang AY, Cotter RJ, Lpasternack GR, Pardoll DM, Jaffee EM (1995) Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem 226:15-25
75. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, freeman GJ, Glimcher LH (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90:6587-5690
76. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
77. Tepper RI (1993) Cytokines and strategies for anticancer vaccines. Contemp Oncol 3:38-53
78. Powrie F, Coffman RL (1993) Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol Today 14:270-274
79. Pardoll DM (1993) New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol 5:719-725
80. Pardoll D (1992) Immunotherapy with cytokine gene-transduced tumor cells: the next wave in gene therapy for cancer. Curr Opin Oncol 4:1124-1129
81. Guinan FC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler L (1994) Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261-3282
82. Chen I, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Lonsley PS (1992) Costimulation of anlitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102
83. Chen L, Linsley PS, Hellstrom KE (1993) Costimulation of T cells for tumor immunity. Immunol Today 14:483-486
84. Bluestone JA (1996) Costimulation and its role in organ transplantation. Clin Transplant 10:104-109
85. Bluestone JA (1995) New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555-559
86. Beverly B, Kang SM, Lenardo MJ, Schwartz RH (1991) Reversal of in vitro T cell clonal anergy by IL-2 stimualtion. Int Immunol 4:661-671
87. Boyer MW, Orchard PJ, Gorden KB, Anderson PM, McLvor RS, Blazar BR (1995) Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8+ T-cell immune response to murine myeloid leukemia. Blood 85:2498-2506
88. Cavallo F, Martin-Eontecha A, Bellone M, Heltai S, Gatti E, Tornaghi P, Freschi M, Forni G, Dellabona P, Casorati G (1995) Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishement of a memory response. Eur J Immunol 25:1154-1162
89. Chong AS, Boussy IA, Jiang XL, Lamas M, Graf LH Jr (1994) CD54/ICAM-1 is a costimulator of NK cell-mediated cytotoxicity. Cell Immunol 157:92-105
90. Damle NK, Klussman K, Linsley PS, Aruffo A, Ledbetter JA (1992) Differential regulatory effects of intercellular adhesion molecule-1 on costimulation by the CD28 counter-receptor B7. J Immunol 149:2541-2548
91. Dubey C, Croft M, Swain SL (1995) Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J Immunol 155:45-57
92. Hirano N, Takahashi T, Ohtake S, Hirashima K, Emi N, Saito K, Hirano M, Shinohara K, Takeuchi M, Taketazu F, Tsunoda S, Ogura M, Omine M, Saito T, Yazaki Y, Ueda R, Hirai H (1996) Expression of costimulatory molecules in human leukemias. Leukemia 10:1168-1176
93. Semnani RT, Nutman TB, Hochman P, Shaw S, van Seventer GA (1994) Costimulation by purified intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 induced distinct proliferation, cytokine and cell surface antigen profiles in human "naive" and "memory" CD4+ T cells. J Exp Med 180:2125-2135
94. Bendall LJ, Kortlepel K, Gottlieb DJ (1995) GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1. Leukemia 9:677-684
95. Tamai L, Zauli G, Bavelloni A, Marmiroli S, Cataldi A, Weber G, Vitale M (1995) Tiazofurin induces a down-modulation of ICAM-1 expression on K562 target cells impairing NK adhesion and killing. Cell Immunol 164:100-104
96. June CH, Bluestone JA, Nadler LM (1994) The B7 and CD28 receptor families. Immunol Today 15:321-331
97. Nandi D, Gross JA, Allison JP (1994) CD28-mediated co-stimulation is necessary for optimal proliferation of murine NK cells. J Immunol 152:3361-3369
98. Allison JP, Hurwitz AA, Leach DR (1995) Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 7:682-686
99. Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368-370
100. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736
101. Townsend SE, Su FW, Atherton JM, Allison JP (1994) Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54:6477-6483
102. Yokochi T, Holly RD, Clark EA (1982) B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts. J Immunol 128:823-827
103. Freedman AS, Freeman G, Horowitz JC, Daley J, Nadler LM (1987) B7 a B-cell-restricted antigen that identifies preactivated B cells. J Immunol 139:3260-3267
104. Yssel H, Schneider PV, Lanier LL (1993) Interleukin-7 specifically induces the B7/BB1 antigen on human cord blood and peripheral blood T cells and T cell clones. Int Immunol 5:753-759
105. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ (1994) Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 180:631-640
106. Valle A, Aubry J-P, Durand I, Banchereau J (1991) IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counterstructure to T cell CD28: an amplification mechanism for T-B cell interactions. Int Immunol 3:229-235
107. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA Jr, Lombard LA, Gray GS, Nadler LM (1993) Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909-911
108. Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ (1993) Identification of an alternative CTLA-4 Iigand costimulatory for T cell activation. Science 263:905-907
109. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du LK, Lombard DB, Gray GS, Nadler LM, Sharpe AH (1993) Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907-909
110. Azuma M, Yssel H, phillips JH, Spits H, Lanier LL (1993) Functional expression of B7/BBI on activated T lymphocytes. J Exp Med 177:845-850
111. Boussiotis VA, freeman GJ, Griben JG, Daley J, Gray G, Nadler LM (1993) Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci USA 90:11059-11063
112. Thompson CB (1995) Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81:979-982
113. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Thl/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707-718
114. Reiser H, Stadecker MJ (1996) Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 335:1369-1377
115. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA (1995) Differential effects of antiB7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 181:1145-1155
116. Yang G, Hellstrom I, Chen L (1995) Antitumor immunity elicited by tumor cells transfected with B7-2 a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 154: 2794-2800
117. Gajewski TF (1996) B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol 156:465-472
118. Aruffo A, Seed B (1987) Molecular cloning of a CD28 CDNA by a high-efficiency COS cell expression system. Proc Natl Acad Sci USA 84:8573-8577
119. June CH, Ledbetter JA, Linsley PS, Thompson CB (1990) Role of the CD28 receptor in T-cell activation. Immunol Today 11:211-216
120. Linsley PS, Ledbetter JA (1993) The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11:191-212
121. Turka LA, linsley PS, Lin H, Brady W, Leiden JM, Wie RQ, Gibson ML, Zheng XG, Myrdal S, Gordon D, Bailey T, Boiling SF, Thompson CB (1992) T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 89:11102-11105
122. Ledhetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P (1985) Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol 135:2331-2336
123. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB (1987) T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 7:4472-4481
124. Hara T, Fu SM, Hansen JA (1985) Human T cell activation: a new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J Exp Med 161:1513-1524
125. Schwartz RH (1992) Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065-1068
126. Brunet J-F, Denizot F, Luciani M-F, Roux-Dosseto M, Suzan M, Mattei MG, Goldstein P (1987) A new member of the immunoglobulin superfamily-CTLA-4. Nature 328:267-270
127. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK (1992) Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 176:1595-1604
128. linsley PS, Wallace PM, Johnson J, Gobson MG, Greene JL, Ledbeter JA, Singh C, Tepper MA (1992) Immunosppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257:792-795
129. Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW (1993) Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609-612
130. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405-413
131. Matulonis U, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD (1995) The role of the B7-1 and B7-2 costimulatory molecules in generating cellular vaccines for the immunotherapy of leukemia. Blood 85:2507-2515
132. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD (1996) B7-1 is superior to B7-2 co-stimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol 156:1126-1131
133. Resnitzky P, Estrov Z, Haran-Ghera N (1985) High incidence of acute myeloid leukemia in SJL/J mice after X-irradiation and corticosteroids. Leukemia Res 9:1519-1528
134. Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, Strom TB, Burakoff SJ, Croop JM, Arceci RJ (1996) Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87:2938-2946
135. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795-1798
136. Dunussi-Joannopoulos K, Krenger W, Weinstein H, Ferrara JL, Croop JM (1997) CDS+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment. Blood 89:2915-2924
137. Warrell RP Jr (1996) Pathogenesis and management of acute promyelocytic leukemia. Ann Rev Med 47:555-565
138. Tallman MS (1996) Differentiating therapy in acute myeloid leukemia. Leukemia 10:1262-1268
139. Olsson I, Bergh G, Ehinger M, Gullberg U (1996) Cell differentiation in acute myeloid leukemia. Eur J Haematol 57:1-16
140. Hodge JW, Abrams S, Schlom J, Kantor JA (1994) Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5525-5555
141. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP (1996) Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 56: 2832-2836
142. McHugh RS, Ahmed SN, Wang YC, Sell KW, Selvaraj P (1995) Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA 92:8059-8063
143. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, kantor JA (1995) Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res 55:3598-3603
144. Fisher-Adams G, Wong KK Jr. Podsakoff G, Forman SJ, Chatterjee S (1996) Integration of adeno-associated virus vectors in CD34+ human heinatopoietic progenitor cells after transduction. Blood 88:492-504
145. Neering SJ, Hardy SF, Minamoto D, Spratt SK, Jordan CT (1996) Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. Blood 88:1147-1155
146. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645-648
147. Terpstra W, Prins A, Ploemacher RE, Wognum BW, Wagemaker G, Lowenberg B, Wielenga JJ (1996) Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia. Blood 87:2187-2194
148. Sutherland HJ, Blair A, Zapf RW (1996) Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 87:4754-4761
149. Hersh EM, Akporiaye E, Harris D, Stopeck AT, Unger EC, Warnecke JA, Kradjian SA (1994) Phase I study of imnumotherapy of malignant melanoma by direct gene transfer. Hum Gene Ther 5:1371-1384
150. Linegan DC, Goedegebuure PS, Eberlein TJ (1996) Vaccine therapy for cancer. Ann Surg Oncol 3:219-228
151. Mukherji B, Chakraborty NG (1995) Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 7:175-184
152. Wallack MK, Sivanandham M. Whooley B, Ditaranto K, Bartolucci AA (1996) Favorable clinical responses in subsets of patients from a randomized. multi-institutional melanoma vaccine trial. Ann Surg Oncol 3:110-117
153. Dengler B (1995) Immunocytochemical and How cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol 89:250-257
154. Boyer M, Vallera DA, Taylor PA, Gray GS, Katsanis E, Gorden K, Orchard PJ, Blazar BR (1997) The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graftversus-leukemia properties. Blood 89:3477-3485
155. Foa R (1993) Does Interleukin-2 have a role in the management of acute leukemia? J Clin Oncol 11:1817-1825
156. Smith KA (1993) Lowest dose interleukin-2 immunotherapy. Blood 8:1414-1423
157. Maraninchi D, Biaise D, Viens P, Brandely M, Olive D, Lopez M, Sainty D, Marit G, Stoppa AM, Reiffers J, Gratecos N, Berlau-Perez P, Mannoni P, Mawas C, hercend T, Sebahoun HG, Carcassonne Y (1991) High-dose recombinant interleukin-2 and acute leukemias in relapse. Blood 78:2182-2187
158. Foa R, Guarini A, Cignetti A, Cronin K, Rosenthal F, Gransbacher B (1994) Cytokine gene therapy: a new strategy for the management of cancer patients. Nat Immun 13:65-75
159. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA (1996) T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 183:2361-2366
160. Foss FM, Koc Y, Stetler-Stevenson MA, Nguyen DT, O'Brien MC, Turner R, Sausville EA (1994) Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sezary syndrome. J Clin Oncol 12:326-335
161. Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL (1995) B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 55:4980-4987
162. Hladik F, Kolbe K, Irschick EU, Aman MJ, Gerken G, Farber L, Liehl E, Peschel C, Aulitzky WE, Huber C (1993) IL-2. IL-3. and IFN-gamma differently affect in vivo frequencies of circulating precursors of cytotoxic T lymphocytes (CTL-P). Ann Hematol 67:67-74
163. Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT (1996) Interleukin-12 and B7,1 costimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 26:1335-1341
164. Salvadori S, Gansbacher B, Wernick I, Tirelli S, Zier K (1995) B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum Gene Ther 6:1299-1306
165. Yang G, Hellstrom KE, Mizuno MT, Chen L (1995) In vitro priming of tumorreactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J Immunol 155:3897-3903
166. Guarini A, Riera L, Cignetti A, Montacchini L, Massaia M, Foa R (1997) Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood 89:212-218
167. Cignetti A, Guarini A, Carbone A, Forni M, Cronin K, Forni G, Gansbacher B, Foa R (1994) Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J Natl Cancer Inst 86:785-791
168. Stingl G, Brocker EB, Mertelsmann R, Wolff K, Schreiber S, Kampgen E, Schneeberger A. Dummer W, Brennscheid U, Veelken H, Birnstiel ML, Zatloukal K, Schmidt W, Maass G, Wagner E, Baschlke M, Giese M, Kempe ER, Weber HA, Voigt T (1996) Phase I study to the immunotherapy of meta-static malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. Hum Gene Ther 7:551-563
169. Veelken H, Mackensen A, Lahn M, Kohler G, Becker D, Franke B, Brennscheidt U, Kulmburg P, Rosenthal FM, Keller H, Hasse J, Sehultze-Seemann W, Farthmann EH, Mertelsmann R, Lindemann A (1997) A phase-1 clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 70:269-277
170. Bodey B, Siegel SE, Kaiser HE (1996) Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies Anticancer Res 16:661-674
171. Demanet C, Brissinck J, De Jonge J, Thielemans K (1996) Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood 87:4390-4398
172. Ely P, Wallace PK, Givan AL, Graziano RF, Cuyre PM, Fanger MW (1996) Bispecific-armed. interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood 87:3813-3921
173. French RR, Bell AJ, Hamblin TJ, Tutt AL, Glennie MJ (1996) Response of B-cell lymphoma to a combination of bispecific antibodies and saporin. Leukemia Res 20:607-617
174. Hsieh-Ma ST, Shi T, Reeder J, Rting DB (1996) In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine. Clin Immunol Immunopathol 80:185-193
175. Katayose Y, Kudo T, Suzuki M, Shinoda M, Saiyo S, Sakurai N, Saeki H, Fukuhara K, Imai K, Matsuno S (1996) MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res 56:4205-4212
176. Lindhofer H, Menzel H, Gunther W, Hultner L, Thierfelder S (1996) Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models. Blood 88: 4651-4658
177. Haas C, Schirrmacher V (1996) Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies. Cancer Immunol Immunother 43:190-194
178. Featherstone C (1996) Bispecific antibodies: the new magic bullets. Lancet 348:536
179. Moreno MB, Titus JA, Cole MS, Tso JY, Le N, Paik CH, T, Zacharchuk CM, Segal DM, Wunderlich JR (1995) Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo. Cancer Immunol Immunother 40:182-190
180. Arceci RJ (1996) Tumor cell survival and resistance to therapy. Curr Opin Hematol 3:279-287